OR43. Immature Platelet Fraction Levels and mayor adverse cardiac events in Acute Coronary Syndrome accompanied by Pneumonia Corona Virus Disease 19

Abstract

Introduction: Acute Coronary Syndrome is a major cardiovascular problem and currently is one of the complications of COVID-19. Immature platelet fraction (IPF) is newly released platelets and have strong thrombotic potential. Recent research has shown that IPF levels are higher in ACS and COVID-19 patients. In this study, we tried to see the IPF levels and ACS outcomes occurred in COVID-19 patients during the hospitalization period. Metods and Results: This study is an analytical observational study with a cohort design that was conducted in August 2020 - December 2020 with 28 sample and follow up during hospitalization. IPF levels In the group following MACE, the IPF median was 5 and in the group that did not following MACE the IPF median was 2.40 . Based on statistical calculations, there were significant differences between the two groups (p=0.004). Meanwhile, the group that following MACE and survivors got a median value 4.90 and grup following MACE and non-survivors a median value of 5.00. Based on statistical calculations, there was no significant difference between the two groups (p=0.670). Conclussion: The IPF level in ACS patients accompanied by covid who occurance MACE was significantly higher than those without MACE. And it was found that the IPF level was higher in non-surviving patients than in non-surviving patients, but it was not statistically significant.